2023 ASCO Genitourinary Cancers Symposium: Focus on renal cell carcinoma

This article describes the main acquisitions of RCC management presented during the 2023 ASCO Genitourinary Cancers Symposium. The efficacy of adjuvant pembrolizumab in patients with resected RCC at increased risk of recurrence was confirmed through a subgroup analysis, and in the metastatic setting, the updated analysis of the CheckMate 9ER study confirmed the efficacy in terms of overall survival of the combination of nivolumab plus cabozantinib. This and other knowledge within the article laid the foundations for further knowledge development necessary for an increasingly personalized management of metastatic RCC.